BG Medicine
Life sciences company developing biomarker-based diagnostic tests for the cardiovascular sectors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | $500k | Post IPO Debt | |
| Total Funding | 000k | ||
Related Content
BG Medicine Inc. specializes in developing and commercializing diagnostic tests that provide critical insights into chronic heart failure. Operating in the healthcare diagnostics market, BG Medicine serves healthcare providers and clinical laboratories. The company's core product, the BGM Test, is an in vitro diagnostic device that measures galectin-3 levels in serum or plasma. This test aids in assessing the prognosis of patients diagnosed with chronic heart failure by providing quantitative data on galectin-3, a biomarker associated with cardiac fibrosis and remodeling. BG Medicine generates revenue through the sale of its diagnostic kits and related services. The business model focuses on leveraging its proprietary technology to offer reliable and precise diagnostic tools that enhance clinical decision-making and patient outcomes.
Keywords: diagnostic tests, chronic heart failure, galectin-3, biomarkers, cardiac fibrosis, healthcare providers, clinical laboratories, in vitro diagnostic, enzyme-linked immunosorbent assay, patient prognosis.